|Place of Origin:||china manufactuer|
|Minimum Order Quantity:||10g|
|Packaging Details:||Special disguised packaging or as your demand|
|Delivery Time:||within 12hours after payment|
|Payment Terms:||T/T, ,|
|Supply Ability:||plent of stock|
|Name:||Pentadecapeptide BPC 157||Alias:||Booly Protection Compound 15, Pentadecapeptide, BPC 157|
peptides for bodybuilding,
no side effect steroids
2mg/vial Human Growth Polypeptide Pentadecapeptide BPC 157 CAS 137525-51-0
1. Pentadecapeptide BPC 157 Details:
Name:Pentadecapeptide BPC 157
Alias : Booly Protection Compound 15, Pentadecapeptide, BPC 157
CAS : 137525-51-0
Sequence : Gly-Glu-Pro-Pro-Pro-Gly- Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
MF : C62H98N16O22
MW : 1419.53552
Purity : 99%
Specification : 2mg/vial
Appearance : White Lyophilized Powder
Standard : USP
Method of Analysis : HPLC
Storage : Lyophilized peptides although stable at room temperature for 3 months, should be stored
desiccated below -18° C. Upon reconstitution of the peptide it should be stored at 4° C between 2-21 days and for future use below -18° C.
2. Pentadecapeptide BPC 157 Specification:
Purity ( HPLC) : 95% min.
Appearance: White powder
Single Impurity ( HPLC) : 2.0% max
Amino Acid Composition:10% of theoretical
Peptide Content ( N% ) : e80.0%
Water Content( Karl Fischer) : d5.0%
Acetate Content ( HPIC) : d15.0%
MS( ESI) : Consistent
Mass Balance: 95.0~ 105.0%
3. Pentadecapeptide BPC 157 Description :
Upon reconstitution of the peptide it should be stored at 4° C between 2-21 days and for future use below -18° C.
Stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, M.W. 1419) may be the new drug stable in human gastric juice, effective both in the upper and lower GI tract, and free of side effects.
BPC 157, in addition to an antiulcer effect efficient in therapy of inflammatory bowel disease (IBD)
(PL 14736) so far only tested in clinical phase II, has a very safe profile, and exhibited a particular
wound healing effect. It also has shown to interact with the NO-saystem, providing endothelium protection and angiogenic effect, even in severely impaired conditions (i.e., it stimulated expression of early growth response 1 gene responsible for cytokine and growth factor generation and early extracellular matrix (collagen) formation (but also its repressor nerve growth factor 1- A binding protein-2)), important to counteract severe complications of advanced and poorly controlled IBD. Hopefully, the lessons from animal studies, particularly advanced intestinal anastomosis healing, reversed short bowel syndrome
and fistula healing indicate BPC 157s high significance in further IBD therapy. Also, this supportive evidence (i.e., no toxic effect, limit test negative, LD1 not achieved, no side effect in trials) may counteract the problems commonly exercised in the use of peptidergic agents, particularly those used on a long-term basis.
4. Pentadecapeptide BPC 157 Application:
1. BPC 157 has a strong anti-inflammatory activity in both acute and chronic inflammation models. In fact, preliminary results in clinical trials suggest that BPC 157 may become an important therapeutic tool for the treatment of inflammatory bowel disease.
2. BPC 157 was shown to accelerate wound healing and to have a marked angiogenic effect. In addition, it significantly facilitates the healing of bone fracture in rats. This peptide also exhibits an osteogenic effect significantly improving the healing of segmental bone defect. BPC 157 accelerates the healing of transected rat Achilles tendon and transected rat quadriceps muscle.
3. FITC-phalloidin staining was able to demonstrate that BPC 157 induces F-actin formation in fibroblasts. Likewise, Western blot analysis was able to detect the production and activation of paxillin and FAK proteins. The western blot analysis also showed that BPC 157 increases the extent of phosphorylation of paxillin and FAK proteins without affecting the amounts produced.
Keywords:BPC 157, intestinal anastomosis, short bowel, colocutaneous fistulas, inflammatory bowel disease, peptidergic agents, anastomosis, pentadecapeptide, antiulcer, clinical phase II
5. Packaging & Delivery
Package Weight :6( Grams )
Delivery Lead Time :Within 24 hours after payment
Minimum Order :10 Vials
Packing methods: Different kinds of special packing methods.
Price:The larger order is,the cheaper price is.Of course, if you want to order samples to test,ok,no problem, the moderate price will be given to you.
Sufficient stock:Sophisticated and professional logistic agent.
Well trained and disciplined packing team:Packing pictures and tacking code are provided within
12 hours after receiving the payment.
Excellent after sale service: Any questions or problems after receiving the product, please feel free
to contact us. Problems would be solved immediately.
6. Recommend Products:
|T-A001 MGF 2mg/vial|
|T-A002 PEG MGF 2mg/vial|
|T-A003 CJC-1295 with DAC 2mg/vial|
|T-A004 CJC-1295 without DAC 2mg/vial|
|T-A005 PT-141 10mg/vial|
|T-A006 MT-1 10mg/vial|
|T-A007 MT-2 10mg/vial|
|T-A008 GHRP-2 5mg/vial|
|T-A008 GHRP-2 10mg/vial|
|T-A009 GHRP-6 5mg/vial|
|T-A009 GHRP-6 10mg/vial|
|T-A010 Ipamorelin 2mg/vial|
|T-A011 Hexarelin 2mg/vial|
|T-A012 Sermorelin 2mg/vial|
|T-A013 Oxytocin 1g, 2mg/vial|
|T-A014 TB500 2mg/vial|
|T-A015 pentadecapeptide BPC 157 2mg//vial|
|T-A016 HGH 176-191 2mg/vial|
|T-A017 Triptorelin 2mg/vial|
|T-A018 Tesamorelin 2mg/vial|
|T-A020 Gonadorelin 2mg/vial|
|T-A020 Gonadorelin 10mg/vial|
|T-A021 DSIP 2mg/vial|
|T-A022 Selank 5mg/vial|
This is part of our hot products,for more products,pls contact me!
Contact Person: Alex